ライフサイエンスコーパス: glycemic control

1 tric patients with T1D after one-year's poor glycemic control.

2 ears or longer at baseline, insulin use, and glycemic control.

3 n pharmacologic therapy is needed to improve glycemic control.

4 stinal glucose absorption in vivo to improve glycemic control.

5 ive period but did not significantly improve glycemic control.

6 ar-daily basis for 24 weeks and had improved glycemic control.

7 Individualized versus uniform intensive glycemic control.

8 - and gender- matched counterparts with good glycemic control.

9 ay be more vulnerable to the insults of poor glycemic control.

10 al for many homeostatic processes, including glycemic control.

11 nts, but little is known about the impact of glycemic control.

12 36E4ORF1 but not Ad5E4ORF1 robustly improved glycemic control.

13 nts with type 2 diabetes, negatively affects glycemic control.

14 (vGMS) is associated with improved inpatient glycemic control.

15 tions among T1D pediatric patients with poor glycemic control.

16 th HbA1c as a surrogate marker indicator for glycemic control.

17 abetes, is a major barrier to achieving good glycemic control.

18 stems, including in aldosterone function and glycemic control.

19 ects on food intake, energy homeostasis, and glycemic control.

20 ry intake than for biomarkers of longer-term glycemic control.

21 ce of posttranscriptional gene regulation in glycemic control.

22 does not appear to be effective in improving glycemic control.

23 nts with type 2 diabetes mellitus under poor glycemic control.

24 ependent therapeutic effects on postprandial glycemic control.

25 y of a fig fruit extract of ABA in promoting glycemic control.

26 to a weight-loss-independent improvement in glycemic control.

27 veness demonstrated therapeutically relevant glycemic control.

28 r for type 2 diabetes that adversely impacts glycemic control.

29 challenge and were associated with improved glycemic control.

30 ons in diabetic patients, despite subsequent glycemic control.

31 their capacities to lose weight and improve glycemic control.

32 associations of various sleep parameters and glycemic control.

33 stribution were associated with more optimal glycemic control.

34 ve treatments to establish and maintain good glycemic control.

35 hormone with extrapancreatic effects beyond glycemic control.

36 abetes mellitus patients under good and poor glycemic control.

37 er label and users of both labels had poorer glycemic control.

38 hout overt cardiovascular disease and stable glycemic control.

39 enewable source of functional beta cells for glycemic control.

40 e hypothalamic ventromedial nucleus (VMN) in glycemic control.

41 support the use of resveratrol for improving glycemic control.

42 ure may lead to more durable weight loss and glycemic control.

43 ons to mitigate socioeconomic disparities in glycemic control.

44 ys a role for negative effects of statins on glycemic control.

45 re risk of developing DKD despite subsequent glycemic control.

46 two injections per day to maintain effective glycemic control.

47 es who may especially benefit from intensive glycemic control.

48 , which impaired systemic insulin action and glycemic control.

49 e diabetes-related biomarkers toward a tight glycemic control.

50 s an estimate of mean blood sugar levels and glycemic control.

51 ith diabetic animals rapidly re-establishing glycemic control.

52 in lower levels of TRLs - without improving glycemic control.

53 w risk of bias for the summary assessment of glycemic control, 15 studies were at unclear risk, and 1

54 one cardiac surgery) to one of two ranges of glycemic control: 80 to 110 mg per deciliter (4.4 to 6.1

55 ignaling pathways contribute to the improved glycemic control achieved with adropin(34-76) treatment

56 Bile acids (BAs) are key mediators of the glycemic control after bariatric surgeries.

57 y and major adverse events despite favorable glycemic control after LVAD implantation.

58 iciency Cohort for DKD phenotypes, including glycemic control, albuminuria, kidney function, and kidn

59 g, sleep apnea, blood pressure, and improved glycemic control, all of which may reduce AF burden.

60 As glycemic control alone does not prevent complications, w

61 ctive effect of NR could not be explained by glycemic control alone.

62 e significantly higher in patients with poor glycemic control, although the plasma levels of both pro

63 he Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults With

64 dults with type 1 diabetes exhibit the worst glycemic control among individuals with type 1 diabetes

65 ded in a clinical setting improved long-term glycemic control among individuals with type 2 diabetes

66 ong-term treatment of periodontal disease on glycemic control among individuals with type 2 diabetes.

67 vitamin D2 from 31 T1D patients with optimal glycemic control and 60 T1D patients with suboptimal gly

68 as an add-on to insulin therapy resulted in glycemic control and a periodontal tissue response to or

69 The authors observed glycemic control and a reduction in body weight, intrahe

70 e analysis revealed association between poor glycemic control and arterial hypertension, presence of

71 control and 60 T1D patients with suboptimal glycemic control and assessed their tolerogenic properti

72 at increased NAD(+) metabolism might address glycemic control and be neuroprotective, we treated pred

73 y during these years is associated with poor glycemic control and complications from diabetes in adul

74 Understanding the genetic basis of glycemic control and HbA(1c) may lead to better preventi

75 This study demonstrates the importance of glycemic control and identifies potential therapeutic ta

76 ralized testing of I and C towards a tighter glycemic control and improved management of diabetes.

77 inflammation of T2D and associates with poor glycemic control and increased T2D morbidity.

78 treatment for 6 months resulted in improved glycemic control and insulin resistance compared with re

79 We sought to assess the effects of intensive glycemic control and intensive blood pressure control on

80 Recipient mice were monitored for glycemic control and intraperitoneal glucose tolerance.

81 nsplant recipients and examined the level of glycemic control and its associated factors, as well as

82 dy (N = 23,294), component GRSs discriminate glycemic control and lipid-based genetic risk, while rev

83 y, continuous glucose monitoring can improve glycemic control and neonatal outcomes in women with typ

84 all margin between a dose that achieves good glycemic control and one that causes hypoglycemia.

85 Despite this, the current level of glycemic control and quality of screening strategies for

86 ith newly diagnosed T1D, rs7804356 predicted glycemic control and residual beta-cell function during

87 te the longitudinal association between poor glycemic control and subsequent changes in retinal micro

88 proposed as a potential target for improving glycemic control and suppressing binge eating behaviors.

89 ected to have consequential bearings on IAPP glycemic control and T2D pathology.

90 d tremendous potential to improve the normal glycemic control and to reduce the incidence of hypergly

91 g that different mechanisms explain improved glycemic control and weight loss after these surgical pr

92 Risk of insulin resistance, impaired glycemic control, and cardiovascular disease is excessiv

93 anic and non-Hispanic black ethnicity, worse glycemic control, and elevated heart rate.

94 dy-composition metrics, appetite, markers of glycemic control, and gut microbiota were measured at 2

95 regain phase, might preserve weight loss and glycemic control, and is associated with specific microb

96 lood pressure, cholesterol and blood lipids, glycemic control, and the use of aspirin) management for

97 specialty journals for articles referring to glycemic control appearing between 2006 and 2015 and ide

98 diabetes and chronic hyperglycaemia, liberal glycemic control appears to attenuate glycemic variabili

99 with more physiological profiles and better glycemic control are needed, especially analogues that p

100 New methods to improve glycemic control are needed.

101 chanism or mechanisms by which leptin exerts glycemic control are unclear.

102 se patterns change as a function of improved glycemic control are warranted.

103 se patterns change as a function of improved glycemic control are warranted.

104 Participants in the intensive glycemic control arm did not have an increased risk of Q

105 ncreased mortality observed in the intensive glycemic control arm in the ACCORD trial is not likely t

106 ms in men) in the intensive versus standard glycemic control arms.

107 peptidase-4 inhibitors are commonly used for glycemic control as adjuncts to metformin, other oral an

108 Greater glycemic control as indicated by >/=1 CGM variable was a

109 iologically with diabetic complications, and glycemic control, as reflected by HbA1c reduction, resul

110 en neighborhood supermarket gain or loss and glycemic control (assessed by glycated hemoglobin (HbA1c

111 imaging was obtained at the end of 1 year of glycemic control assessment.

112 iabetes, supporting a mechanism for improved glycemic control associated with maintenance of function

113 ries for those with good, moderate, and poor glycemic control at baseline, while supermarket gain was

114 T1D, and the duration of diabetes, age, and glycemic control at the time of initial photography were

115 s and Children Hospital, 28 of whom had poor glycemic control (average glycated hemoglobin [HbA1c] >/

116 basal insulin also correlated with efficient glycemic control (blood glucose <120 mg/dL), prevention

117 Visual acuity, glycemic control, blood pressure, human immunodeficiency

118 uding anthropometric indices, blood factors, glycemic control, blood pressure, lipid tests, and liver

119 ucocorticoids (GCs) are essential for proper glycemic control, but in excess, can lead to hyperglycem

120 father had childhood type 1 diabetes in poor glycemic control, but lacked the mutation and had neithe

121 ell accepted that physical activity improves glycemic control, but the knowledge on underlying mechan

122 e neighborhood foreclosure rate could worsen glycemic control by activating stressors such as higher

123 These injectable analogs achieve robust glycemic control by increasing concentrations of "GLP-1

124 The certainty of evidence for glycemic control by subgroup was moderate for multicompo

125 ed with standard glycemic control, intensive glycemic control caused increased mortality in the Actio

126 uclei, correlated inversely with measures of glycemic control, cerebrovascular burden and depression

127 lifestyle intervention results in equivalent glycemic control compared with standard care and, second

128 ave concluded that sleep contributes to poor glycemic control, diabetes management, and diabetes-rela

129 treatment strategies developed strictly for glycemic control did not confer a large risk reduction i

130 conclude that patients with T1DM and stable glycemic control display enhanced platelet activation co

131 Furthermore, intensive glycemic control does not lead to improved patient-cente

132 mized clinical trials suggest that intensive glycemic control does not reduce major macrovascular eve

133 day-and-night closed-loop therapy maintained glycemic control during a high proportion of the time in

134 l and neonatal outcomes, and optimization of glycemic control during pregnancy can help mitigate risk

135 ia and diabetic ketoacidosis and with better glycemic control during the most recent year of therapy.

136 , increases energy expenditure, and improves glycemic control equally well in mice treated with antib

137 Most RCTs of intensive vs standard glycemic control excluded adults older than 80 years, us

138 >/=9.0%) had the worst associated changes in glycemic control following either supermarket loss or ga

139 A) in the blood, are essential indicators of glycemic control for diabetes mellitus.

140 an Hb, this could indicate a recent lapse in glycemic control for that patient.

141 that encourage an individualized approach to glycemic control for U.S. adults with type 2 diabetes re

142 residual C-peptide that likely contribute to glycemic control.FUNDINGFunding for this work was provid

143 ementation had no effect on GLP-1 secretion, glycemic control, gastric emptying, body weight, or ener

144 Intensive glycemic control has been a major focus for clinical tri

145 However, early loss of glycemic control has been observed with metformin monoth

146 Second, although glycemic control has been recommended as a part of compr

147 Neither poor glycemic control (HbA1c >/=9.0%, adjusted HR: 1.04, 95%

148 s (P < 0.0001), insulin use (P = 0.002), and glycemic control (HbA1C < 7%) (P = 0.002) were used to d

149 Adequate glycemic control (HbA1c < 7%) was achieved in 66.7% of t

150 Long-term glycemic control (HbA1c <7%) was seen in 63% of patients

151 Among patients with relapse, 67% maintained glycemic control (HbA1c <7%).

152 27 age- and gender-matched subjects had good glycemic control (HbA1c <8%).

153 n Americans with diabetes mellitus varies by glycemic control, health status, and calendar year (befo

154 The other group showed no improvement in glycemic control (HOMA-IR mean change: -0.26; 95% CI: -0

155 er nut consumption is associated with better glycemic control; however, it is unclear if this associa

156 lanted, beta cell grafts can help to restore glycemic control; however, locating and retrieving cells

157 Intensive glycemic control (IGC) targeting HbA1c fails to show an

158 ammatory responses in the liver and improved glycemic control immediately after allogeneic PITx and s

159 l trials consistently suggest that intensive glycemic control immediately increases the risk of sever

160 Although intensive glycemic control improves outcomes in type 1 diabetes me

161 , blood pressure was below 140/90 mm Hg, and glycemic control in 85% up to 15 years after onset.

162 ype 1 diabetes therapies that afford tighter glycemic control in a more manageable and painless manne

163 borhood supermarket presence did not benefit glycemic control in a substantive way.

164 centives on glucose monitoring adherence and glycemic control in adolescents and young adults with ty

165 e monitoring (CGM) has been shown to improve glycemic control in adults, its benefit in adolescents a

166 ffect of tree nuts and peanuts on markers of glycemic control in adults.

167 ing and modifying barriers impeding improved glycemic control in black persons with diabetes.

168 A treat-to-target approach led to good glycemic control in both groups, and there was no signif

169 t it is unclear whether short period of poor glycemic control in children with T1D can cause evident

170 ent effect was fully attributed to the prior glycemic control in DCCT (explained treatment effect: 10

171 K effectively regulates liver metabolism and glycemic control in diabetic mice in a LKB1-dependent ma

172 We assessed whether poor glycemic control in Hp 1-1 carriers is more strongly ass

173 d standard procedure for assessing long term glycemic control in individuals with diabetes mellitus a

174 ing cells offers the potential for restoring glycemic control in individuals with diabetes.

175 widely used to diagnose diabetes and assess glycemic control in individuals with diabetes.

176 ype 2 diabetes may be effective in improving glycemic control in LMICs, but few studies are available

177 ation that correlated with an improvement of glycemic control in men with T2DM.

178 Primary outcomes were adequate GWG and glycemic control in mothers and birth weight, birth leng

179 the rhythmic release of insulin and diurnal glycemic control in normal male and female mice.

180 blockade similarly improved inflammation and glycemic control in obese WT mice.

181 ere is substantial uncertainty about optimal glycemic control in older adults with type 2 diabetes me

182 important predictor of ischemic stroke than glycemic control in patients who have diabetes and AF.

183 to diagnose type 2 diabetes (T2D) and assess glycemic control in patients with diabetes.

184 ontinuous positive airway pressure (CPAP) on glycemic control in patients with diabetes.

185 ffect of positive airway pressure therapy on glycemic control in patients with relatively well-contro

186 about the impact of tight versus less tight glycemic control in patients with type 2 diabetes mellit

187 ) induce substantial weight loss and improve glycemic control in patients with type 2 diabetes, but i

188 hether a lifestyle intervention can maintain glycemic control in patients with type 2 diabetes.

189 abel subcutaneous semaglutide (secondary) on glycemic control in patients with type 2 diabetes.

190 fects of treating obstructive sleep apnea on glycemic control in patients with type 2 diabetes.

191 d self-monitored glucose results in improved glycemic control in people with poorly controlled type 2

192 AG) is an emerging biomarker used to monitor glycemic control in persons with diabetes.

193 evelop new approaches to achieve near-normal glycemic control in real-world settings in people with t

194 ification including weight loss and improved glycemic control in reducing arrhythmia recurrence follo

195 e and health by examining annual measures of glycemic control in relation to local foreclosure activi

196 ery may achieve better and more long-lasting glycemic control in select patients with early-onset T2D

197 fer a novel therapeutic target for improving glycemic control in subjects with T2D.

198 pharmacologic approaches for safer intensive glycemic control in T1DM.

199 subcutaneous adipocyte size predicted better glycemic control in T2D.

200 The incretin hormones improve glycemic control in T2DM by increasing insulin secretion

201 SIRT6 may be a viable strategy for improving glycemic control in T2DM.

202 as a clinical solution to improve long-term glycemic control in the context of diabetes.

203 rum concentrations of Activin B and improved glycemic control in the db/db mouse model of T2D.

204 ovide a more complete picture of a patient's glycemic control in the months leading up to blood colle

205 ce that increased foreclosure rates worsened glycemic control in this continuously insured population

206 Poor glycemic control in Type 1 Diabetes (T1D) patients is st

207 Intensive glycemic control in type 2 diabetes (glycated hemoglobin

208 The challenges of achieving optimal glycemic control in type 2 diabetes highlight the need f

209 nt on GLP-1 secretion, gastric emptying, and glycemic control in type 2 diabetes.

210 f dietary intake with multiple indicators of glycemic control in youth with type 1 diabetes participa

211 g dietary intake variables with time-varying glycemic control indicators, controlling for age, height

212 Compared with standard glycemic control, intensive glycemic control caused incr

213 quality and macronutrient distribution with glycemic control is ambiguous.

214 Poor glycemic control is associated with cardiac autoimmunity

215 Recent evidence suggests that glycemic control is associated with cognitive function i

216 Poor glycemic control is associated with increased risk of ca

217 from several studies suggest that intensive glycemic control is associated with QT prolongation, whi

218 most patients with type 1 diabetes, adequate glycemic control is not achieved with insulin therapy al

219 Of note, current glycemic control is not associated significantly with ei

220 Optimal glycemic control is particularly difficult to achieve in

221 The extended glycemic control led to distinctive improvements on redu

222 significantly impaired insulin sensitivity, glycemic control, lipid metabolism, and sympathetic outp

223 These findings suggest that glycemic control may be improved by increasing intake of

224 obesity and diabetes have become common and glycemic control may be poor.

225 T1 contributes to the coordinated efforts in glycemic control may ultimately present novel therapeuti

226 Participants who had diabetes had poor glycemic control (mean [+/-SD] glycated hemoglobin level

227 nalyses of contemporary randomized trials of glycemic control measuring patient-important microvascul

228 Optimization of glycemic control, medication regimens, and careful atten

229 d T2DM, we examined analytes associated with glycemic control, metabolic processes, and T-cell-driven

230 as all SC islet recipients failed to restore glycemic control (n = 0 of 10, P < 0.01, log-rank).

231 a-level attributes and according to baseline glycemic control (near normal, <6.5%; good, 6.5%-7.9%; m

232 gests that periodontal treatment may improve glycemic control of patients with DMt2 by eliminating pe

233 Glycemic control often deteriorates during adolescence a

234 red twice daily via s.c. injection, improves glycemic control, often with associated weight reduction

235 We aimed to examine the impact of improved glycemic control on left ventricular (LV) function in th

236 ity after transplantation, but the effect of glycemic control on survival is unknown.We sought to det

237 lure cannot be explained by their actions on glycemic control or as osmotic diuretics.

238 ripheral, or hepatic IR or in any measure of glycemic control or beta-cell function.

239 were found between groups regarding maternal glycemic control or neonatal outcomes.

240 rsons than in white persons are due to worse glycemic control or racial differences in the glycation

241 s to assess the overall long-term functional glycemic control or the possibility of unrecognized diab

242 oglycemia and are associated with suboptimal glycemic control outcomes.

243 but statistically significant improvement in glycemic control over 26 weeks.

244 basal insulin), was efficacious in improving glycemic control over 52 weeks.

245 Improvements in glycemic control over a 12-month period led to improveme

246 ases in postprandial gut hormone secretions, glycemic control, pancreas morphology, and micronutrient

247 Poor glycemic control profoundly affects protein expression a

248 sought to determine the relationship between glycemic control (random blood glucose [RBG], fasting bl

249 betes mellitus (aged 54+/-10 years) and poor glycemic control received optimization of treatment for

250 erapy to insulin in T1DM, heralding improved glycemic control, reduced body weight and total daily in

251 Achieving glycemic control remains a challenge for patients with t

252 of type 1 diabetes (T1D) treatment; however, glycemic control remains a challenge.

253 During surgery, glycemic control should be implemented using blood gluco

254 od pressure control, lipid control, diabetic glycemic control, smoking cessation, and target body mas

255 lationship between social adversity and poor glycemic control specially in urban areas of Bangladesh.

256 1c concentration were not available, and the glycemic control status was evaluated according to FPG v

257 Glycemic control strongly correlates with survival after

258 active in rats, with an in vivo potency for glycemic control surpassing that of native GLP-1.

259 ith hyperglycemia did not benefit from tight glycemic control targeted to a blood glucose level of 80

260 In multicenter studies, tight glycemic control targeting a normal blood glucose level

261 LDL and duration of T1D, patients with poor glycemic control tended to have marginally wider retinal

262 iabetes, oral semaglutide resulted in better glycemic control than placebo over 26 weeks.

263 tomated) insulin delivery can provide better glycemic control than sensor-augmented pump therapy, but

264 d with standard care resulted in a change in glycemic control that did not reach the criterion for eq

265 ocioeconomic status (SES) is related to poor glycemic control, the underlying mechanisms remain uncle

266 ht changes, on energy-metabolism metrics and glycemic control.The study was a randomized, controlled,

267 ere restricted to those with poorer baseline glycemic control, those with more severe sleep apnea, or

268 Preconception glycemic control through appropriate methods is one of t

269 Interventions to improve glycemic control through early intensive treatment of di

270 (1) R blockade in mice with obesity improves glycemic control through the hepatic Sirt1/mTORC2/Akt pa

271 TDM patients had satisfactory and comparable glycemic control throughout the follow-up period.

272 ion of whether or not to recommend intensive glycemic control to patients to minimize microvascular a

273 ndrial function in the regulation of optimal glycemic control to prevent T2D, but parkin's role in pr

274 l policy statements about the value of tight glycemic control to reduce micro- and macrovascular comp

275 in the association between low SES and poor glycemic control using data from the baseline survey of

276 d, 632 with type 2 diabetes and insufficient glycemic control using diet and exercise alone or a stab

277 IN5 on hepatic lipid metabolism and systemic glycemic control using liver-specific Plin5-deficient mi

278 in a daily insulin dose reduction and major glycemic control versus I-T1D.

279 Glycemic control was inadequate in 33.3% of LT recipient

280 Glycemic control was not associated with AAb prevalence

281 rovided evidence that between 2007 and 2010, glycemic control was not associated with rates of comple

282 Dose-related worsening of glycemic control was noted in 14.5% of patients who rece

283 The improvement in glycemic control was observed without stimulation of the

284 high levels of obesity, diabetes was common, glycemic control was poor, and diabetes was associated w

285 Glycemic control was poorer in diabetic individuals with

286 1R expression is thought to be influenced by glycemic control, we examined the effect of blood glucos

287 patic interaction of Ad36E4ORF1 in enhancing glycemic control, we expressed E4ORF1 of Ad36 or Ad5 or

288 samples for analyzing HbA1c concentrations (glycemic control) were collected in the mobile examinati

289 or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considere

290 of PECs to differentiate in vivo and restore glycemic control while confirming minimal proliferation

291 f peripheral neuropathy is to maintain close glycemic control, while there is no recommendation for c

292 peutic strategies focusing solely on optimal glycemic control with currently available drugs or appro

293 erapeutic potential owing to its long-acting glycemic control with improved cardiovascular function a

294 diabetes mellitus who do not achieve optimal glycemic control with insulin monotherapy, is the additi

295 lycemic medications are necessary to balance glycemic control with safety.

296 igh-fat diet, Ocy-PPARgamma(-/-) mice retain glycemic control, with increased browning of the adipose

297 effects of the housing foreclosure crisis on glycemic control within a population of patients with di

298 creasing systemic inflammation and providing glycemic control without increasing insulin, ABA extract

299 o determine whether a " liberal" approach to glycemic control would reduce hypoglycemia and glycemic

300 rition management is critical to maintaining glycemic control, yet it is difficult to achieve due to